SLS CIK: 1390478

SELLAS Life Sciences Group, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
millions USD
FY21:
23.0
FY22:
17.8
FY23:
3.17
FY24:
16.3
FY25:
75.2
(positive)
Change from FY21 to FY25
millions USD
FY21:
3.23
FY22:
3.19
FY23:
3.05
FY24:
3.11
FY25:
3.13
Total assets
Change from FY21 to FY25
millions USD
FY21:
26.3
FY22:
20.9
FY23:
6.22
FY24:
19.4
FY25:
78.3

Liabilities & Equity

(negative)
Change from FY21 to FY25
millions USD
FY21:
4.98
FY22:
15.5
FY23:
13.7
FY24:
9.51
FY25:
7.02
(negative)
Change from FY21 to FY25
millions USD
FY21:
0.95
FY22:
0.58
FY23:
0.46
FY24:
0.46
FY25:
0.46
(positive)
Change from FY21 to FY25
millions USD
FY21:
20.3
FY22:
4.85
FY23:
−7.98
FY24:
9.47
FY25:
70.9
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
26.3
FY22:
20.9
FY23:
6.22
FY24:
19.4
FY25:
78.3

All amounts in millions USD Data source:SEC EDGAR